HomeCompareBBL vs ABBV

BBL vs ABBV: Dividend Comparison 2026

BBL yields 57.25% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BBL wins by $133.2K in total portfolio value
10 years
BBL
BBL
● Live price
57.25%
Share price
$64.18
Annual div
$36.74
5Y div CAGR
-7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$235.5K
Annual income
$29,079.36
Full BBL calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — BBL vs ABBV

📍 BBL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBBLABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BBL + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BBL pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BBL
Annual income on $10K today (after 15% tax)
$4,865.85/yr
After 10yr DRIP, annual income (after tax)
$24,717.46/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, BBL beats the other by $3,661.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BBL + ABBV for your $10,000?

BBL: 50%ABBV: 50%
100% ABBV50/50100% BBL
Portfolio after 10yr
$168.9K
Annual income
$26,925.56/yr
Blended yield
15.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BBL
Analyst Ratings
8
Buy
19
Hold
2
Sell
Consensus: Hold
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BBL buys
0
ABBV buys
0
No recent congressional trades found for BBL or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBBLABBV
Forward yield57.25%3.06%
Annual dividend / share$36.74$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-7%40.6%
Portfolio after 10y$235.5K$102.3K
Annual income after 10y$29,079.36$24,771.77
Total dividends collected$171.4K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: BBL vs ABBV ($10,000, DRIP)

YearBBL PortfolioBBL Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$16,024$5,323.81$11,550$430.00+$4.5KBBL
2$24,560$7,414.59$13,472$627.96+$11.1KBBL
3$36,157$9,877.57$15,906$926.08+$20.3KBBL
4$51,327$12,638.93$19,071$1,382.55+$32.3KBBL
5$70,514$15,594.19$23,302$2,095.81+$47.2KBBL
6$94,070$18,620.55$29,150$3,237.93+$64.9KBBL
7$122,246$21,590.87$37,536$5,121.41+$84.7KBBL
8$155,190$24,386.63$50,079$8,338.38+$105.1KBBL
9$192,961$26,907.88$69,753$14,065.80+$123.2KBBL
10$235,548$29,079.36$102,337$24,771.77+$133.2KBBL

BBL vs ABBV: Complete Analysis 2026

BBLStock

BHP Group Limited operates as a resources company in Australia, Europe, China, Japan, India, South Korea, rest of Asia, North America, South America, and internationally. It operates through Petroleum, Copper, Iron Ore, and Coal segments. The company engages in the exploration, development, and production of oil and gas properties; and mining of copper, silver, zinc, molybdenum, uranium, gold, iron ore, and metallurgical and energy coal. It is also involved in mining, smelting, and refining of nickel; and potash development activities. In addition, the company provides towing, freight, marketing and trading, marketing support, finance, administrative, and other services. The company was founded in 1851 and is headquartered in Melbourne, Australia.

Full BBL Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BBL vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BBL vs SCHDBBL vs JEPIBBL vs OBBL vs KOBBL vs MAINBBL vs JNJBBL vs MRKBBL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.